OverviewSuggest Edit

Orchard Therapeutics is a biotechnology company, develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases, and hematological disorders. The сompany also develops adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex-vivo lentiviral gene therapy programs.
TypePublic
Founded2015
HQLondon, GB
Websiteorchard-tx.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2019)252
Revenue (FY, 2018)£1.7 M
Share Price (Jul 2021)$3.4
Cybersecurity ratingCMore

Key People/Management at Orchard Therapeutics

Bobby Gaspar

Bobby Gaspar

Chief Executive Officer, Director
John Cerio

John Cerio

Chief Human Resource Officer
Adrien Lemoine

Adrien Lemoine

Chief Business Officer
Anne Dupraz-Poiseau

Anne Dupraz-Poiseau

Chief Development Officer
John Ilett

John Ilett

Chief of Staff, Chief Legal Officer & Company Secretary
Frank Thomas

Frank Thomas

President & Chief Operating Officer
Show more

Orchard Therapeutics Office Locations

Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park
London, GB (HQ)
108 Cannon St
Boston, MA, US
101 Seaport Blvd 7th floor
Boston, MA, US
2 Seaport Ln 8th floor
Foster City, CA, US
1118 Chess Dr
Menlo Park, CA, US
1360 O'Brien Dr
Show all (5)

Orchard Therapeutics Financials and Metrics

Orchard Therapeutics Revenue

Orchard Therapeutics's revenue was reported to be £1.66 m in FY, 2018
GBP

Revenue (FY, 2018)

1.7m

Gross profit (FY, 2018)

1.3m

Gross profit margin (FY, 2018), %

79.7%

Net income (FY, 2018)

(184.4m)

EBIT (FY, 2018)

(188.0m)

Market capitalization (15-Jul-2021)

423.3m

Closing stock price (15-Jul-2021)

3.4

Cash (31-Dec-2018)

268.7m

EV

154.6m
Orchard Therapeutics's current market capitalization is $423.3 m.
GBPFY, 2018

Revenue

1.7m

Cost of goods sold

337.6k

Gross profit

1.3m

Gross profit Margin, %

80%
GBPFY, 2017FY, 2018

Cash

71.9m268.7m

Accounts Receivable

997.6k1.7m

Current Assets

75.4m284.4m
GBPFY, 2017FY, 2018

Cash From Operating Activities

(26.0m)(78.0m)

Cash From Investing Activities

(1.2m)(3.2m)

Cash From Financing Activities

92.6m283.9m

Net Change in Cash

65.3m202.6m
GBPFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Orchard Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Orchard Therapeutics Online and Social Media Presence

Embed Graph

Orchard Therapeutics News and Updates

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema

Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications

Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA

Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders

Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments

$150M Strategic Financing Supports Execution into the First Half of 2023

Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021

BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences:

Thinking about buying stock in Novan, Baudax Bio, Tyme Technologies, Orchard Therapeutics, or electroCore?

NEW YORK, Feb. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, BXRX, TYME, ORTX, and ECOR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Orchard Therapeutics Blogs

Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates

Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates Content Import Thu, 05/13/2021 - 07:01 Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates May 13, 2021 at 7:01 AM EDT …

Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™

Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™ Content Import Wed, 03/03/2021 - 09:01 Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard T…

Patient Engagement in the Era of Gene Therapy

The post Patient Engagement in the Era of Gene Therapy appeared first on Orchard Therapeutics.

Orchard Therapeutics Secures Partnerships to Broaden Access to Libmeldy™ for Eligible Patients in Middle East & Turkey

BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN, two leading regional

Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)

Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD) Content Import Thu, 01/14/2021 - 07:00 Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Thera…

Emma Nealon

Emma Nealon Jonathan.Lorin… Mon, 01/11/2021 - 15:07 Emma Nealon Cantor Fitzgerald
Show more

Orchard Therapeutics Frequently Asked Questions

  • When was Orchard Therapeutics founded?

    Orchard Therapeutics was founded in 2015.

  • Who are Orchard Therapeutics key executives?

    Orchard Therapeutics's key executives are Bobby Gaspar, John Cerio and Adrien Lemoine.

  • How many employees does Orchard Therapeutics have?

    Orchard Therapeutics has 252 employees.

  • What is Orchard Therapeutics revenue?

    Latest Orchard Therapeutics annual revenue is £1.7 m.

  • What is Orchard Therapeutics revenue per employee?

    Latest Orchard Therapeutics revenue per employee is £6.6 k.

  • Who are Orchard Therapeutics competitors?

    Competitors of Orchard Therapeutics include Verve Therapeutics, AID Genomics and Annexon Biosciences.

  • Where is Orchard Therapeutics headquarters?

    Orchard Therapeutics headquarters is located at 108 Cannon St, London.

  • Where are Orchard Therapeutics offices?

    Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park.

  • How many offices does Orchard Therapeutics have?

    Orchard Therapeutics has 5 offices.